The BCD-089 (aIL6R) in Patients With Active Rheumatoid Arthritis
Status:
Completed
Trial end date:
2019-10-22
Target enrollment:
Participant gender:
Summary
The study is Phase II randomized, double-blind, placebo-controlled clinical trial to evaluate
efficacy and safety, pharmacokinetics and pharmacodynamics of 2 dosing regimens (qw and q2w,
s/c) of monoclonal antibody to IL6R (BCD-089) in patients with active rheumatoid arthritis
and inadequate response to methotrexate.